journal article·2019-12-04Open access

MiR-629-3p-induced downregulation of SFTPC promotes cell proliferation and predicts poor survival in lung adenocarcinoma

Bin Li, Yu-Qi Meng, Zheng Li, Ci Yin, Jun-Ping Lin, Duo-Jie Zhu, Shao-Bo Zhang

Abstract

The long-term prognosis of patients with lung cancer remains poor and thus it is imminent to further elucidate the molecular mechanism for the oncogenesis of lung cancer. In this study, we observed that surfactant protein C (SFTPC) expression was downregulated in human lung adenocarcinoma tissues and cell lines, and low SFTPC expression correlated with poor overall survival of lung adenocarcinoma patients. Moreover, we found that overexpression of SFTPC could inhibit lung cancer cell proliferation in vitro and in vivo, but downregulation of SFTPC showed the opposite results. Besides, it was observed that miR-629-3p expression was upregulated in human lung adenocarcinoma tissues and cell lines. More importantly, we found that miR-629-3p could downregulate SFTPC expression by directly binding to the SFTPC 3'-UTR and inhibit the regulatory effect of SFTPC on lung adenocarcinoma cell proliferation. In conclusion, these data suggested that miR-629-3p-meditated downregulation of SFTPC may promote lung adenocarcinoma progression.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Neonatal Respiratory Health Research · S100 Proteins and Annexins · Ocean Waves and Remote Sensing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou University Second Clinical Medical College

References (37)

Show source-provided references
1. 10.3322/caac.2126210.3322/caac.21262 ↗
2. 10.3322/caac.2149210.3322/caac.21492 ↗
3. 10.3322/caac.2155110.3322/caac.21551 ↗
4. 10.3322/caac.2133810.3322/caac.21338 ↗
5. 10.1186/s12943-017-0705-910.1186/s12943-017-0705-9 ↗
6. 10.1038/nature2518310.1038/nature25183 ↗
7. 10.1056/NEJMra02238710.1056/NEJMra022387 ↗
8. 10.1038/nri152810.1038/nri1528 ↗
9. 10.1016/j.molimm.2004.07.01410.1016/j.molimm.2004.07.014 ↗
10. 10.1172/JCI1688910.1172/JCI16889 ↗
11. 10.4049/jimmunol.172.12.759210.4049/jimmunol.172.12.7592 ↗
12. 10.1016/j.bpj.2010.09.03910.1016/j.bpj.2010.09.039 ↗
13. 10.1038/onc.2015.26610.1038/onc.2015.266 ↗
14. 10.1186/s12885-017-3285-610.1186/s12885-017-3285-6 ↗
15. 10.1038/onc.2017.25310.1038/onc.2017.253 ↗
16. 10.3389/fimmu.2018.0112610.3389/fimmu.2018.01126 ↗
17. 10.3389/fimmu.2018.0184410.3389/fimmu.2018.01844 ↗
18. 10.1158/1078-0432.CCR-04-208710.1158/1078-0432.CCR-04-2087 ↗
19. 10.1002/jcp.2557210.1002/jcp.25572 ↗
20. 10.1016/j.ajpath.2013.01.03010.1016/j.ajpath.2013.01.030 ↗
21. 10.1200/JCO.2013.50.610510.1200/JCO.2013.50.6105 ↗
22. 10.1158/1078-0432.CCR-06-159310.1158/1078-0432.CCR-06-1593 ↗
23. 10.1016/j.freeradbiomed.2019.05.01710.1016/j.freeradbiomed.2019.05.017 ↗
24. 10.1016/j.csbj.2016.05.00510.1016/j.csbj.2016.05.005 ↗
25. 10.1080/21691401.2019.161772710.1080/21691401.2019.1617727 ↗
26. Sheedy P, Medarova Z. The fundamental role of miR-10b in metastatic cancer. Am J Cancer Res. 2018;8:1674–1688.
27. 10.1080/21691401.2019.161772810.1080/21691401.2019.1617728 ↗
28. 10.1159/00049395610.1159/000493956 ↗
29. 10.3389/fimmu.2019.0000610.3389/fimmu.2019.00006 ↗
30. 10.1038/s41388-018-0588-210.1038/s41388-018-0588-2 ↗
31. 10.7150/jca.2768610.7150/jca.27686 ↗
32. 10.1042/BSR2017168710.1042/BSR20171687 ↗
33. 10.3390/genes901001610.3390/genes9010016 ↗
34. 10.1080/21691401.2018.146445910.1080/21691401.2018.1464459 ↗
35. 10.1038/s41598-019-40629-z10.1038/s41598-019-40629-z ↗
36. 10.21037/atm.2019.02.4010.21037/atm.2019.02.40 ↗
37. 10.1186/s13058-017-0865-y10.1186/s13058-017-0865-y ↗